Crinetics Pharmaceuticals, Inc. (CRNX)
- Previous Close
44.01 - Open
44.05 - Bid 42.96 x 100
- Ask 43.05 x 200
- Day's Range
42.87 - 44.54 - 52 Week Range
15.76 - 49.58 - Volume
524,785 - Avg. Volume
818,985 - Market Cap (intraday)
3.352B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-3.69 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
57.92
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
www.crinetics.comRecent News: CRNX
Performance Overview: CRNX
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRNX
Valuation Measures
Market Cap
3.35B
Enterprise Value
2.84B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
622.10
Price/Book (mrq)
6.21
Enterprise Value/Revenue
708.54
Enterprise Value/EBITDA
-12.84
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.18%
Return on Equity (ttm)
-50.16%
Revenue (ttm)
4.01M
Net Income Avi to Common (ttm)
-214.53M
Diluted EPS (ttm)
-3.69
Balance Sheet and Cash Flow
Total Cash (mrq)
558.56M
Total Debt/Equity (mrq)
9.59%
Levered Free Cash Flow (ttm)
-93.53M
Research Analysis: CRNX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell